Clinical Management of Pediatric Acute-Onset Neuropsychiatric Syndrome: Part I-Psychiatric and Behavioral Interventions.
Autor: | Thienemann M; 1 Stanford University , Stanford, California., Murphy T; 2 University of South Florida , St. Petersburg, Florida., Leckman J; 3 Yale University , New Haven, Connecticut., Shaw R; 1 Stanford University , Stanford, California., Williams K; 4 Massachusetts General Hospital , Boston, Massachusetts., Kapphahn C; 1 Stanford University , Stanford, California., Frankovich J; 1 Stanford University , Stanford, California., Geller D; 5 Harvard Medical School , Boston, Massachusetts., Bernstein G; 6 University of Minnesota , Minneapolis, Minnesota., Chang K; 1 Stanford University , Stanford, California., Elia J; 7 Nemours, Alfred I dupont Hospital for Children , Wilmington, Delaware., Swedo S; 8 National Institute of Mental Health , Bethesda, Maryland. |
---|---|
Jazyk: | angličtina |
Zdroj: | Journal of child and adolescent psychopharmacology [J Child Adolesc Psychopharmacol] 2017 Sep; Vol. 27 (7), pp. 566-573. Date of Electronic Publication: 2017 Jul 19. |
DOI: | 10.1089/cap.2016.0145 |
Abstrakt: | Objective: This article outlines the consensus guidelines for symptomatic treatment for children with Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) and Pediatric Autoimmune Neuropsychiatric Syndrome Associated with Streptococcal Infection (PANDAS). Methods: Extant literature on behavioral, psychotherapeutic, and psychopharmacologic treatments for PANS and PANDAS was reviewed. Members of the PANS Research Consortium pooled their clinical experiences to find agreement on treatment of PANS and PANDAS symptoms. Results: Current guidelines result from consensus among the Consortium members. Conclusion: While underlying infectious and inflammatory processes in PANS and PANDAS patients are treated, psychiatric and behavioral symptoms need simultaneous treatment to decrease suffering and improve adherence to therapeutic intervention. Psychological, behavioral, and psychopharmacologic interventions tailored to each child's presentation can provide symptom improvement and improve functioning during both the acute and chronic stages of illness. In general, typical evidence-based interventions are appropriate for the varied symptoms of PANS and PANDAS. Individual differences in expected response to psychotropic medication may require marked reduction of initial treatment dose. Antimicrobials and immunomodulatory therapies may be indicated, as discussed in Parts 2 and 3 of this guideline series. |
Databáze: | MEDLINE |
Externí odkaz: |